New asthma drug IBI3002 passes first safety check in small study
NCT ID NCT06213844
First seen Nov 21, 2025 · Last updated May 14, 2026 · Updated 18 times
Summary
This early-stage study tested a single dose of a new drug called IBI3002 in 52 healthy adults and people with mild-to-moderate asthma. The main goal was to check if the drug is safe and how the body processes it. Participants were randomly assigned to receive either the drug or a placebo, and were followed for about 5 weeks after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia
Conditions
Explore the condition pages connected to this study.